Intermittent Letermovir Dosing in Cytomegalovirus High-Risk Liver Transplant Recipients May Facilitate Development of Cell-Mediated Immunity and Prevent Post-Prophylaxis Infection.

Prevymis (letermovir) - Merck (MSD)

Intermittent Letermovir Dosing in Cytomegalovirus High-Risk Liver Transplant Recipients May Facilitate Development of Cell-Mediated Immunity and Prevent Post-Prophylaxis Infection. (PubMed, Transpl Infect Dis) - May 20, 2026 - No abstract available
Journal • Cytomegalovirus Infection • Infectious Disease • Transplantation

http://www.ncbi.nlm.nih.gov/pubmed/42154149

Chris M Saddler; Hanna L Kleiboeker; Margaret R Jorgenson

May 20, 2026